Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease

Michael Eliasziw, James Kennedy, Michael D. Hill, Alastair M. Buchan, Henry J.M. Barnett, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group

Abstract

Background: Transient ischemic attacks (TIAs) often herald a stroke, but little is known about the acute natural history of TIAs. Our objective was to quantify the early risk of stroke after a TIA in patients with internal carotid artery disease.

Methods: Using patient data from the medical arm of the North American Symptomatic Carotid Endarterectomy Trial, we calculated the risk of ipsilateral stroke in the territory of the symptomatic internal carotid artery within 2 and 90 days after a first-recorded hemispheric TIA. We also studied similar outcomes among patients in the trial who had a first-recorded completed hemispheric stroke.

Results: For patients with a first-recorded hemispheric TIA (n = 603), the 90-day risk of ipsilateral stroke was 20.1% (95% confidence interval [CI] 17.0%–23.2%), higher than the 2.3% risk (95% CI 1.0%–3.6%) for patients with a hemispheric stroke (n = 526). The 2-day risks were 5.5% and 0.0%, respectively. Patients with more severe stenosis of the internal carotid artery (> 70%) appeared to be at no greater risk of stroke than patients with lesser degrees of stenosis (adjusted hazard ratio 1.1, 95% CI 0.7–1.7). Infarct on brain imaging (adjusted hazard ratio 2.1, 95% CI 1.5–3.0) and the presence of intracranial major-artery disease (adjusted hazard ratio 1.9, 95% CI 1.3–2.7) doubled the early risk of stroke in patients with a hemispheric TIA.

Interpretation: Patients who had a hemispheric TIA related to internal carotid artery disease had a high risk of stroke in the first few days after the TIA. Early risk of stroke was not affected by the degree of internal carotid artery stenosis.

Methods

The NASCET was a randomized, multicentre clinical trial designed to determine the efficacy of carotid endarterectomy among patients with ischemic symptoms associated with internal carotid artery disease. Patients were enrolled in the trial if they had had a retinal or hemispheric TIA or a completed retinal or hemispheric ischemic stroke within 180 days before randomization. A retinal TIA was defined as a partial or complete visual field loss in 1 eye of ischemic origin lasting less than 24 hours. A hemispheric TIA was defined as a focal cerebral dysfunction of ischemic origin lasting less than 24 hours. A stroke was defined as a neurological dysfunction of ischemic origin with deficits persisting longer than 24 hours. The trial protocol was approved by the institutional review board at each participating centre, and written informed consent was obtained from each patient.

From December 1987 to December 1996, patients were randomly assigned to best contemporary medical care (n = 1449) or best contemporary medical care plus carotid endarterectomy (n = 1450).
1436) and followed to the end of December 1997. Details of the methods and final results have been published. Patients were not eligible if they had a probable cardiac source of embolism or a serious disease likely to cause death within 5 years. Patients with disabling stroke before randomization were also excluded.

All patients underwent a detailed medical examination at baseline, including echocardiography and chest radiography. CT or MRI scanning of the brain was performed before randomization to determine the presence of infarcts and to rule out structural lesions that could have caused stroke-like symptoms. The degree of internal carotid artery stenosis was measured from a conventional carotid angiogram using strict criteria. Patient follow-up consisted of clinical examinations at 30 days, at 3, 6, 9 and 12 months, and every 4 months thereafter.

Data collection for this trial included a face-to-face patient interview in which all ischemic events occurring within 180 days before randomization were recorded. Clinical details of ischemic events, including type, duration and number, were collected as part of the trial protocol by the participating stroke neurologist. A written narrative of the patient's medical history was included in the case report form. Following data collection, all events were scrutinized by the trial’s medical data managers and stroke fellows and were reconciled with the written narrative.

The territory and type of stroke (ischemic or hemorrhagic) occurring during follow-up were centrally reviewed. The presumed cause of each ischemic stroke was designated as large-artery, lacunar or cardioembolic. Definition of lacunar strokes was based on conformity with the 5 classic lacunar syndromes, with or without deep lesions that could have caused stroke-like symptoms. The degree of internal carotid artery stenosis was measured from a conventional carotid angiogram using strict criteria. Patient follow-up consisted of clinical examinations at 30 days, at 3, 6, 9 and 12 months, and every 4 months thereafter.

Data collection for this trial included a face-to-face patient interview in which all ischemic events occurring within 180 days before randomization were recorded. Clinical details of ischemic events, including type, duration and number, were collected as part of the trial protocol by the participating stroke neurologist. A written narrative of the patient’s medical history was included in the case report form. Following data collection, all events were scrutinized by the trial’s medical data managers and stroke fellows and were reconciled with the written narrative.

The territory and type of stroke (ischemic or hemorrhagic) occurring during follow-up were centrally reviewed. The presumed cause of each ischemic stroke was designated as large-artery, lacunar or cardioembolic. Definition of lacunar strokes was based on conformity with the 5 classic lacunar syndromes, with or without deep lesions that could have caused stroke-like symptoms. The degree of internal carotid artery stenosis was measured from a conventional carotid angiogram using strict criteria. Patient follow-up consisted of clinical examinations at 30 days, at 3, 6, 9 and 12 months, and every 4 months thereafter.

Data collection for this trial included a face-to-face patient interview in which all ischemic events occurring within 180 days before randomization were recorded. Clinical details of ischemic events, including type, duration and number, were collected as part of the trial protocol by the participating stroke neurologist. A written narrative of the patient’s medical history was included in the case report form. Following data collection, all events were scrutinized by the trial’s medical data managers and stroke fellows and were reconciled with the written narrative.

Eliasziw et al

Table 1: Characteristics of patients whose first-recorded event was hemispheric TIA or hemispheric stroke

| Characteristic                      | Hemispheric TIA | Hemispheric stroke | p value* |
|------------------------------------|-----------------|--------------------|----------|
| Age ≥ 75 yr†                        | 116 (19.2)      | 91 (17.3)          | 0.40     |
| Male sex                           | 411 (68.2)      | 368 (70.0)         | 0.51     |
| Hypertension                       | 366 (60.7)      | 326 (62.0)         | 0.66     |
| Diabetes mellitus                  | 128 (21.2)      | 133 (25.3)         | 0.11     |
| Myocardial infarction or angina    | 263 (43.6)      | 182 (34.6)         | 0.002    |
| Hyperlipidemia                     | 226 (37.5)      | 181 (34.4)         | 0.28     |
| Smoking in the past year           | 259 (43.0)      | 205 (39.0)         | 0.18     |
| Degree of ICA stenosis‡            |                 |                    |          |
| < 50%                              | 307 (50.9)      | 281 (53.4)         |          |
| 50%–69%                            | 157 (26.0)      | 166 (31.6)         | 0.002§   |
| 70%–99%                            | 139 (23.1)      | 79 (15.0)          |          |
| Irregular or ulcerated ICA plaque‡ | 334 (55.4)      | 250 (47.5)         | 0.008    |
| Infarct on brain imaging‡          | 229 (38.0)      | 327 (62.2)         | < 0.001  |
| Intracranial disease of major artery‡ | 196 (32.5)   | 169 (32.1)         | 0.89     |
| Duration of symptoms ≥ 10 min      | 380 (63.0)      | –                  | –        |

Notes: TIA = transient ischemic attack; ICA = internal carotid artery.
*Computed from a χ² test comparing proportions.
†Mean age (and standard deviation) of patients: 66.4 (8.7) and 66.4 (8.4) years, respectively.
‡Ipsilateral to the territory of the first-recorded ischemic symptoms.
§For overall association between degree of ICA stenosis and type of event.

Results

Of the 1449 patients randomly assigned to the medical arm of the trial, 320 had a first-recorded retinal event (TIA 252, stroke 68) and were excluded from further analyses. Of the remaining 1129 patients, 603 (53.4%) had a hemispheric TIA and 526 (46.6%) had a hemispheric stroke as the first-recorded event (Table 1). The mean age was 66.4 years (standard deviation [SD] 8.6), and vascular risk factors were common to the 2 groups. The median duration of a
hemispheric TIA was 15 minutes (interquartile range 5–60 minutes; for 72.1% the duration was less than 1 hour, and for 7.6% it was ≥ 6 hours).

A total of 133 patients had an ipsilateral stroke within 90 days after the first-recorded event. The 90-day risk of ipsilateral stroke was higher among patients who had had a hemispheric TIA than among those who had had a hemispheric stroke (20.1%, 95% confidence interval [CI] 17.0%–23.2% v. 2.3%, 95% CI 1.0%–3.6%; logrank test \( p < 0.001 \)) (Fig. 1). About one-quarter of the 90-day stroke risk (i.e., 5.5% of 20.1%) accrued within 48 hours after the hemispheric TIA. The event-free survival curves became parallel at about 60 days. There were no hemorrhagic events.

Although in most cases the stroke was large-artery in origin, more patients in the hemispheric TIA group than in the hemispheric stroke group had a lacunar stroke (37.2% v. 8.3%; \( \chi^2 \) test \( p = 0.043 \)). The occurrence of cardioembolic stroke was low (0.8% and 0.0% respectively).

When the hemispheric TIA patients were stratified by degree of stenosis, the event-free survival curves for ipsilateral stroke were virtually indistinguishable (logrank test \( p = 0.93 \), Fig. 2). The early hazard of ipsilateral stroke was not increased by severe (70%–99%) internal carotid artery stenosis (adjusted hazard ratio 1.1, 95% CI 0.7–1.7, Table 2). Except for infarct visible on brain imaging (adjusted hazard ratio 2.1, 95% CI 1.5–3.0) and the presence of intracranial major-artery disease (adjusted hazard ratio 1.9,
95% CI 1.3–2.7), hazard ratios associated with other characteristics were close to 1. The 90-day risk of ipsilateral stroke increased with symptom duration in patients with hemispheric TIA, but was not statistically significant (log-rank test \( p = 0.58 \), test for trend \( p = 0.34 \), Fig. 3).

**Interpretation**

This study demonstrated that the risk of ipsilateral stroke among patients with symptomatic internal carotid artery disease was 5.5% within the first 2 days after a first-recorded hemispheric TIA and 20.1% in the first 90 days. The 90-day risk was not affected by the degree of stenosis. The risk was lower among patients with a first-recorded hemispheric stroke than among patients with a first-recorded hemispheric TIA. In about two-thirds of the patients who had an ipsilateral stroke, it was large-artery in origin, which implicated the newly symptomatic internal carotid artery. The cause was cardioembolic in few of the cases of stroke, because patients harbouring a probable cardiogenic stroke were excluded from entry into the trial.

A previous study reported that older age, diabetes mellitus and duration of symptoms were predictors of early stroke in patients diagnosed with a TIA. In our study, increased risk of stroke was significantly associated only with infarct visible on brain imaging and the presence of intracranial major-artery disease. Risk of stroke did increase with longer duration of symptoms, but the result did not reach statistical significance. The difference in risk factors is primarily due to the different case-mix of patients in these studies; our study included only patients with symptomatic internal carotid artery disease.

The large randomized trials demonstrating the efficacy of carotid endarterectomy for symptomatic internal carotid artery stenosis reported a positive relation between degree of stenosis and long-term risk of stroke. In our study, the degree of stenosis did not affect the early risk of stroke. The high early risk of stroke might, therefore, be the result of a ruptured plaque in a stenosed carotid artery. However, if this were the only mechanism for stroke occurrence, then the risk of stroke would have been the same for patients presenting with a completed stroke as for those with a hemispheric TIA. The striking disparity between the 2 groups observed in our study suggests other mechanisms that are unclear at this time. New imaging techniques may shed some light by making accurate visualization of the carotid plaque possible and allow characterization of the effect of plaque instability on stroke risk.

Almost 75% of the patients with a hemispheric TIA had symptoms that lasted less than 1 hour. The number of patients who had hemispheric TIA symptoms persisting beyond 1 hour diminished with time, which is congruent with the proposed new definition for TIA, namely the longer that symptoms persist, the less likely they are to resolve.

Because TIA is a historical clinical diagnosis, the results of this trial are limited by the ability of patients to recall their symptoms. This difficulty is shared by all studies of TIA. However, because the stroke neurologists participating in this trial specifically collected detailed information about ischemic events occurring 180 days before randomization, every attempt was made to minimize the effects of poor recall.

In conclusion, a hemispheric TIA in the presence of internal carotid artery disease confers a high risk of stroke in the immediate aftermath of the artery becoming symptomatic. Concerted efforts to conduct randomized trials focusing solely on the acute phase are now required to determine optimal intervention strategies for stroke prevention.

---

**Fig. 3:** The 90-day risk of ipsilateral stroke by duration of first-recorded hemispheric TIA. Error bars = 95% confidence intervals.
Early stroke risk after transient ischemic attack

References

1. TIAT/mini strokes: public knowledge and experience (Roper Starch World-wide survey). Englewood (CO): National Stroke Association; 2000.

2. Graves RJ. *Clinical lectures on the practice of medicine*. London: New Sydenham Society; 1844.

3. Chiari H. Ueber das Verhalten des Teilungswinkels der Carotis communis bei der Endarteritis chronic deformans. *Verh Dtsch Ges Pathol* 1905;9:326-30.

4. Fisher CM. Occlusion of the internal carotid arteries. *Arch Neurol Psychiatry* 1951;65:546-77.

5. Johnston SC, Gross DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. *JAMA* 2000;284(22):2901-6.

6. Whisnant JP, Matsumoto N, Elvehack LR. Transient cerebral ischemic attacks in a community. *Mayo Clin Proc* 1973;48(3):194-8.

7. Whisnant JP, Wisbers DO, O’Fallon WM, Sicks JD, Frye RL. Effect of time since onset of risk factors on the occurrence of ischemic stroke. *Neurology* 2002;58(5):787-94.

8. Dennis MS, Bamford JM, Sandercock PA, Warlow CP. A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes. *Stroke* 1989;20(11):1494-9.

9. Bousser MG, Eschwege E, Haguenaui M, Lefaucconnier JM, Thibult N, Touboul D, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. *Stroke* 1983;14(1):5-14.

10. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med* 1978;299(2):53-9.

11. Fieldt WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. *Stroke* 1977;8(3):301-14.

12. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simon-Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med* 1978;299(2):53-9.

13. Bousser MG, Eschwege E, Haguenaui M, Lefaucconnier JM, Thibult N, Touboul D, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. *Stroke* 1983;14(1):5-14.

14. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med* 1978;299(2):53-9.

15. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. *N Engl J Med* 1991;325(18):1261-6.

16. Hass WK, Easton JD, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing tiolopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. *N Engl J Med* 1989;321(8):501-7.

17. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *N Engl J Med* 1991;338(8779):1341-9.

18. American–Canadian Co-Operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. *J Neurol Neurosurg Psychiatry* 1991;54(12):1044-54.

19. Barnett HJM. Transient cerebral ischemia. *Ann R Coll Physic Surg Can* 1974;7:154-73.

20. Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angiographic features of carotid transient ischemic attacks. *N Engl J Med* 1977;296(7):358-62.

21. Diener H, Canha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996;143(1-2):1-13.

22. Barnett HJM, Mohr JP, Stein BM, Yatsu FM, editors. *Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators*. *N Engl J Med* 1998;339(15):1415-25.

23. Fox AJ. How to measure carotid stenosis. *Radiology* 1993;186(2):316-8.

24. Inzitari D, Eliazziz M, Sharpe BL, Fox AJ, Barnett HJ. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. *Neurology* 2000;54(3):660-6.

25. Barnett HJM, Guntion RW, Eliazziz M, Fleming L, Sharpe B, Gates P, et al. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. *JAMA* 2000;283(11):1429-36.

26. Barnett HJM, Guntion RW, Eliazziz M, Fleming L, Sharpe B, Gates P, et al. Prognosis after transient monocular blindness associated with carotid-artery stenosis. *N Engl J Med* 2001;344(15):1084-90.

27. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998;351(9113):1379-87.